Trial Profile
Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation Positive NSCLC With Acquired Resistance to First or Third Generation EGFR TKIs
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 15 Apr 2022
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Necitumumab (Primary)
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 14 Apr 2022 Status changed from recruiting to discontinued.
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 21 Jan 2021 Planned End Date changed from 1 Dec 2022 to 1 Jul 2023.